Scientists Find Second Site for Prostate Cancer Gene

	Tweet

Scientists at Wake Forest University School of Medicine and colleagues who are studying a prostate cancer gene called HNF1B have found a second independent site within the HNF1B gene on chromosome 17 (17q12) – increasing the number of genetic variants that may contribute to risk of developing the disease.

After comparing the newly-discovered site with a previously discovered site in the same gene among two large groups of patients in Sweden and at Johns Hopkins Hospital in Baltimore, “these data strongly suggest that the two sites are genetically independent,” said Jianfeng Xu, M.D., Dr. Ph.H., senior researcher on the study.

“We found another genetic variant associated with prostate cancer risk,” Xu said. “The more genetic variants we discover, the better off we are. As we find more of these, it improves our ability to predict prostate cancer risk.”

Xu, a professor of epidemiology and cancer biology and Director of the Center for Cancer Genomics, reported the results with 30 colleagues in the current on-line version of Nature Genetics.

The researchers conducted what they termed a “fine-mapping study” in the two groups, one called CAPS, from Sweden, that had 2,899 prostate cancer cases and 1,722 control participants, and the Johns Hopkins study that had 1,527 prostate cancer patients and 482 control participants.

They found two separate clusters of prostate-cancer-associated SNPs (single nucleotide polymorphisms), one in a region previously identified and one in a new region. The researchers then worked to see whether the genetic variants were associated with risk of developing the disease. They looked at the same locations in five other large studies of prostate cancer patients and found that prostate cancer risk was higher among men who had the genetic variants.

Earlier this year, the same research group reported in the New England Journal of Medicine that genetic variants have a strong cumulative effective. A man with four of the five previously discovered variants has a 400 percent increased risk of developing prostate cancer compared to men with none of the variants.

Xu said that as the number of genetic variants associated with prostate cancer risk continues to mount, it improves the precision of risk prediction. But he predicted that prostate cancer will be found to be polygenic, “not dependent on one gene, but a group of genes.”

Prostate cancer risk might be plotted on a bell-shaped curve, with men with a family history of the disease and multiple variants being at the upper end of the curve.

The researchers are exploring another finding, that the HNF1B gene is also associated with diabetes. But if a patient with the HNF1B gene has diabetes, the prostate cancer risk decreases, “We still don’t know how,” Xu said.

Collaborating with Xu were William B. Isaacs, Ph.D., from the Department of Urology at Johns Hopkins Medical Institutions in Baltimore, and Henrik Grönberg, M.D., Ph.Dl, from Karolinska Institute in Stockholm, Sweden.

Jielin Sun, Ph.D., and S. Lilly Zheng, M.D., of the Center for Cancer Genomics and the Center for Human Genomics at Wake Forest, are co-first authors of the paper. Additional co-authors from Wake Forest’s cancer genomics and human genomics centers are Lina D. Purcell, M.S., Zhengrong Gao, B.S., Seong-Tae Kim, Ph.D., Wennuan Liu, Ph.D., Yi Zhu, B.S., Latchezar Dimitrov, M.S., Jishan Sun, Ph.D., Tao Li, M.D., Ph.D., Aubrey R. Turner, M.S., Tamara S. Adams, M.S., and Bao-Li Chang, Ph.D. Fang-Chi Hsu is from the Department of Biostatistical Sciences at Wake Forest.

Wake Forest University Baptist Medical Center (http://www.wfubmc.edu) is an academic health system comprised of North Carolina Baptist Hospital, Brenner Children’s Hospital, Wake Forest University Physicians, and Wake Forest University Health Sciences, which operates the university’s School of Medicine and Piedmont Triad Research Park. The system comprises 1,154 acute care, rehabilitation and long-term care beds and has been ranked as one of “America’s Best Hospitals” by U.S. News & World Report since 1993. Wake Forest Baptist is ranked 32nd in the nation by America’s Top Doctors for the number of its doctors considered best by their peers. The institution ranks in the top third in funding by the National Institutes of Health and fourth in the Southeast in revenues from its licensed intellectual property.

Source: Wake Forest University Baptist Medical Center

RELATED STORIES:
Scientists discover genetic variant associated with prostate cancer in African Americans   New data show benefit of finasteride in preventing prostate cancer   Herbal extract may treat prostate cancer   Novel association between Parkinson’s disease and prostate cancer   Genetic and Behavioral Differences Add to Prostate Cancer Disparities   Gene test could save men from prostate surgery   New Study Strengthens Association of Prostate Cancer with Exposure to Agent Orange in Vietnam Vetera   CCNY researchers demonstrate effectiveness of contrast agent Cytate in detectcing prostate cancer   Shorter radiation course as effective as standard therapy for prostate cancer recurrence   Prostate cancer surgery more costly for obese men   Obesity-linked High Blood Volumes Render PSA Prostate Cancer Test Less Effective   Many prostate cancers don’t need radical therapy   New Treatment for Advanced Prostate Cancer   Prostate cancer risk increased in obese men: study   Ack1 molecule stimulates the aggressive growth of prostate cancer   deCODE discovers genetic markers that improve the power of PSA testing for detecting prostate cancer   Brisk walking may help men with prostate cancer, UCSF study finds   Sometimes No Treatment is the Right Option for Low-Risk Prostate Cancer   Pomegranate Juice Slows PSA Acceleration Rate After Prostate Cancer Surgery, Radiation   Variances in patterns of care for patients with prostate cancer failing primary therapy   Prostate cancer screening improves quality of life by catching disease before it spreads   Prostate cancer gene test provides new early detection

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]